Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone.

Overexpression of human epidermal growth factor receptor 2 (HER-2/neu) characterizes a molecular subtype of breast cancer associated with poor clinical outcome. Preventive strategies for HER-2/neu-positive breast cancer, which is often estrogen and progesterone receptor negative, remain undefined. Activators of peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear hormone receptor also expressed in breast cancer, hold potential as cancer prevention agents. PPARgamma ligands include specific fatty acids and synthetic compounds, such as the thiazolidinediones, which appear to inhibit cell proliferation and tumorigenesis. We hypothesized that a thiazolidinedione, rosiglitazone, may serve as a chemopreventive agent for HER-2/neu-associated mammary carcinogenesis, but that efficacy may be influenced by dietary fat content. We studied the effects of diets enriched with corn or fish oil (25% of energy) with and without rosiglitazone (12 g/kg) in a 2 x 2 factorial design on mammary tumorigenesis in murine mammary tumor virus (MMTV)-HER-2/neu transgenic mice. Despite in vitro evidence of antiproliferative effects in an MMTV-HER-2/neu tumor cell line, rosiglitazone did not affect mammary carcinogenesis in vivo. Interestingly, fish oil-based diets markedly suppressed breast tumor incidence (57% of mice vs. 87% of corn oil-fed mice, P = 0.0001) as well as tumor multiplicity (P = 0.001) and mammary gland dysplasia (P = 0.001). These findings demonstrate a potent preventive effect of (n-3) PUFA on HER-2/neu-mediated mammary carcinogenesis, without interaction with a synthetic PPARgamma activator. Further studies focusing on the mechanisms by which (n-3) fatty acids suppress HER-2/neu signaling pathways involved in the pathogenesis of breast cancer are warranted.

[1]  C. J. Barnes,et al.  HER2 Regulation of Peroxisome Proliferator-activated Receptor γ (PPARγ) Expression and Sensitivity of Breast Cancer Cells to PPARγ Ligand Therapy , 2003 .

[2]  S. Suster,et al.  The Antiproliferative Effects of PPARγ Ligands in Normal Human Mammary Epithelial Cells , 2003, Breast Cancer Research and Treatment.

[3]  J. Piette,et al.  A Proinflammatory Role for the Cyclopentenone Prostaglandins at Low Micromolar Concentrations: Oxidative Stress-Induced Extracellular Signal-Regulated Kinase Activation Without NF-κB Inhibition1 , 2002, The Journal of Immunology.

[4]  M. Pignatelli,et al.  The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. , 2001, Journal of cell science.

[5]  W. Hsueh,et al.  Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. , 2001, Biochemical and biophysical research communications.

[6]  G. Atsumi,et al.  Magnitude of Peroxisome Proliferator-Activated Receptor-γ Activation is Associated With Important and Seemingly Opposite Biological Responses in Breast Cancer Cells , 2001, Journal of Investigative Medicine.

[7]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[8]  P. Triozzi,et al.  Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.

[9]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[10]  E. Williamson,et al.  A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. , 2000, Journal of the National Cancer Institute.

[11]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[12]  H. Bartsch,et al.  Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. , 1999, Carcinogenesis.

[13]  M. Sporn,et al.  A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .

[14]  V. Seewaldt,et al.  Peroxisome proliferator-activated receptor gamma activation in human breast cancer. , 1999, International journal of oncology.

[15]  M. Willingham,et al.  Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. , 1999, Carcinogenesis.

[16]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[17]  M. Lerner,et al.  Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands. , 1998, Biochemical and biophysical research communications.

[18]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[19]  J. G. Alvarez,et al.  Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.

[20]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[22]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[23]  W. T. Cave.  Omega-3 polyunsaturated fatty acids in rodent models of breast cancer , 1997, Breast Cancer Research and Treatment.

[24]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[25]  J. Tugwood,et al.  A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. , 1996, European journal of biochemistry.

[26]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[27]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[28]  D. Rose,et al.  Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. , 1995, Journal of the National Cancer Institute.

[29]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[30]  Y. Yarden,et al.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.

[31]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[32]  D. Rose,et al.  Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. , 1993, Journal of the National Cancer Institute.

[33]  P. G. Reeves,et al.  AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. , 1993, The Journal of nutrition.

[34]  C. Ip.  Controversial issues of dietary fat and experimental mammary carcinogenesis. , 1993, Preventive medicine.

[35]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y. Yarden,et al.  Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. , 1992, The Journal of biological chemistry.

[37]  Michael J. González,et al.  Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. , 1991, Carcinogenesis.

[38]  D. Rose,et al.  Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. , 1990, Cancer research.

[39]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[40]  R. Mansel,et al.  Lipids in breast carcinogenesis , 1989, The British journal of surgery.

[41]  C. Beattie,et al.  Differential proliferative response to linoleate in cultures of epithelial cells from normal human breast and fibroadenomas. , 1989, Cancer research.

[42]  G. McKnight,et al.  The MMTV LTR promoter is induced by progesterone and dihydrotestosterone but not by estrogen. , 1988, Molecular endocrinology.

[43]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[44]  J. Marsh,et al.  Effect of omega-3 fatty acids on growth of a rat mammary tumor. , 1984, Journal of the National Cancer Institute.

[45]  J. Jurkowski,et al.  Dietary lipid effects on the growth, membrane composition, and prolactin-binding capacity of rat mammary tumors. , 1984, Journal of the National Cancer Institute.

[46]  D. Rose,et al.  Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice. , 1997, Nutrition and cancer.

[47]  R. Cardiff,et al.  Signaling Exacerbates Mammary Gland Tumor Development Γ Ppar Material Supplemental , 2022 .